While these findings suggest the potential benefits of initiating AZT/IFN-containing regimens early in the disease course, it is important to note that more research with an adequate sample size of indolent patients is needed to precisely investigate the effect of the AZT/IFN regimen in the early stages of ATLL. The gene discussed is IFNA1; the disease is adult T-cell leukemia/lymphoma.